SCHEMBL25845505

SCHEMBL25845505

CC(=O)CC1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 5/20 0.55
CASP6 P55212 1/20 0.55
MAPT P10636 7/20 0.46
GAA P10253 5/20 0.46
KDM4E B2RXH2 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
RAD52 P43351 1/20 0.46
ALDH1A1 P00352 6/20 0.46
KMT2A Q03164 2/20 0.46
ADRA2C P18825 1/20 0.46
PTK2B Q14289 1/20 0.46
ESR2 Q92731 1/20 0.46
USP2 O75604 2/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43
THRB P10828 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15650145 0.86 GFER (0.49) GFERCASP6MAPTGAAKDM4E
SCHEMBL132858 0.86 FFAR4 (0.53) GFERCASP6MAPTGAAKDM4E
SCHEMBL5777417 0.84 NOTUM (0.50) MAPTKMT2AUSP2NPSR1L3MBTL1
SCHEMBL13114895 0.84 GFER (0.48) GFERCASP6MAPTGAAKDM4E
SCHEMBL132391 0.81 LGMN (0.48) GFERCASP6MAPTGAAKDM4E
SCHEMBL25167745 0.81 GFER (0.51) GFERCASP6MAPTGAAKDM4E
SCHEMBL25845507 0.80 MAPT (0.60) MAPTSMN1; SMN2ALDH1A1KMT2AHTT
SCHEMBL21418385 0.79 GFER (0.60) GFERCASP6MAPTGAAKDM4E
SCHEMBL27628738 0.79 GFER (0.49) GFERCASP6MAPTGAAKDM4E
SCHEMBL1789020 0.78 MAPT (0.58) GFERCASP6MAPTGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 GFER 4686/4885CASP6 2108/4885MAPT 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.